Lung cancer: intragenic ERBB2 kinase mutations in tumours

Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Christopher Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S. Cooper; Adrienne M. Flanagan; Margaret Knowles; Suet Y. Leung; David N. Louis; Leendert H. J. Looijenga; Bruce Malkowicz; Marco A. Pierotti; Bin Teh; Georgia Chenevix-trench; Barbara L. Weber; Siu T. Yuen; Grace Harris; Peter Goldstraw; Andrew G. Nicholson; P. Andrew Futreal; Richard Wooster; Michael R. Stratton

doi:10.1038/431525b

Lung cancer: intragenic ERBB2 kinase mutations in tumours

Philip Stephens, Chris Hunter, Graham Bignell, Sarah Edkins, Helen Davies, Jon Teague, Claire Stevens, Sarah O'meara, Raffaella Smith, Adrian Parker, Andy Barthorpe, Matthew Blow, Lisa Brackenbury, Adam Butler, Oliver Clarke, Jennifer Cole, Ed Dicks, Angus Dike, Anja Drozd, Ken EdwardsSimon Forbes, Rebecca Foster, Kristian Gray, Christopher Greenman, Kelly Halliday, Katy Hills, Vivienne Kosmidou, Richard Lugg, Andy Menzies, Janet Perry, Robert Petty, Keiran Raine, Lewis Ratford, Rebecca Shepherd, Alexandra Small, Yvonne Stephens, Calli Tofts, Jennifer Varian, Sofie West, Sara Widaa, Andrew Yates, Francis Brasseur, Colin S. Cooper, Adrienne M. Flanagan, Margaret Knowles, Suet Y. Leung, David N. Louis, Leendert H. J. Looijenga, Bruce Malkowicz, Marco A. Pierotti, Bin Teh, Georgia Chenevix-trench, Barbara L. Weber, Siu T. Yuen, Grace Harris, Peter Goldstraw, Andrew G. Nicholson, P. Andrew Futreal, Richard Wooster, Michael R. Stratton

Research output: Contribution to journal › Article › peer-review

682 Citations (Scopus)

Abstract

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

Original language	English
Pages (from-to)	525-526
Number of pages	2
Journal	Nature
Volume	431
Issue number	7008
DOIs	https://doi.org/10.1038/431525b
Publication status	Published - 30 Sep 2004

Keywords

Carcinoma, Non-Small-Cell Lung
DNA Mutational Analysis
Enzyme Activation
Humans
Lung Neoplasms
Models, Molecular
Mutation
Neoplasms
Protein Structure, Tertiary
Quinazolines
Receptor, Epidermal Growth Factor
Receptor, erbB-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/431525b

Cite this

Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'meara, S., Smith, R., Parker, A., Barthorpe, A., Blow, M., Brackenbury, L., Butler, A., Clarke, O., Cole, J., Dicks, E., Dike, A., Drozd, A., ... Stratton, M. R. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature, 431(7008), 525-526. https://doi.org/10.1038/431525b

@article{f16788f9d32e4f55b574ff72dd98ff41,

title = "Lung cancer: intragenic ERBB2 kinase mutations in tumours",

abstract = "The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.",

keywords = "Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Enzyme Activation, Humans, Lung Neoplasms, Models, Molecular, Mutation, Neoplasms, Protein Structure, Tertiary, Quinazolines, Receptor, Epidermal Growth Factor, Receptor, erbB-2",

author = "Philip Stephens and Chris Hunter and Graham Bignell and Sarah Edkins and Helen Davies and Jon Teague and Claire Stevens and Sarah O'meara and Raffaella Smith and Adrian Parker and Andy Barthorpe and Matthew Blow and Lisa Brackenbury and Adam Butler and Oliver Clarke and Jennifer Cole and Ed Dicks and Angus Dike and Anja Drozd and Ken Edwards and Simon Forbes and Rebecca Foster and Kristian Gray and Christopher Greenman and Kelly Halliday and Katy Hills and Vivienne Kosmidou and Richard Lugg and Andy Menzies and Janet Perry and Robert Petty and Keiran Raine and Lewis Ratford and Rebecca Shepherd and Alexandra Small and Yvonne Stephens and Calli Tofts and Jennifer Varian and Sofie West and Sara Widaa and Andrew Yates and Francis Brasseur and Cooper, {Colin S.} and Flanagan, {Adrienne M.} and Margaret Knowles and Leung, {Suet Y.} and Louis, {David N.} and Looijenga, {Leendert H. J.} and Bruce Malkowicz and Pierotti, {Marco A.} and Bin Teh and Georgia Chenevix-trench and Weber, {Barbara L.} and Yuen, {Siu T.} and Grace Harris and Peter Goldstraw and Nicholson, {Andrew G.} and Futreal, {P. Andrew} and Richard Wooster and Stratton, {Michael R.}",

year = "2004",

month = sep,

day = "30",

doi = "10.1038/431525b",

language = "English",

volume = "431",

pages = "525--526",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7008",

}

Stephens, P, Hunter, C, Bignell, G, Edkins, S, Davies, H, Teague, J, Stevens, C, O'meara, S, Smith, R, Parker, A, Barthorpe, A, Blow, M, Brackenbury, L, Butler, A, Clarke, O, Cole, J, Dicks, E, Dike, A, Drozd, A, Edwards, K, Forbes, S, Foster, R, Gray, K, Greenman, C, Halliday, K, Hills, K, Kosmidou, V, Lugg, R, Menzies, A, Perry, J, Petty, R, Raine, K, Ratford, L, Shepherd, R, Small, A, Stephens, Y, Tofts, C, Varian, J, West, S, Widaa, S, Yates, A, Brasseur, F, Cooper, CS, Flanagan, AM, Knowles, M, Leung, SY, Louis, DN, Looijenga, LHJ, Malkowicz, B, Pierotti, MA, Teh, B, Chenevix-trench, G, Weber, BL, Yuen, ST, Harris, G, Goldstraw, P, Nicholson, AG, Futreal, PA, Wooster, R & Stratton, MR 2004, 'Lung cancer: intragenic ERBB2 kinase mutations in tumours', Nature, vol. 431, no. 7008, pp. 525-526. https://doi.org/10.1038/431525b

TY - JOUR

T1 - Lung cancer

T2 - intragenic ERBB2 kinase mutations in tumours

AU - Stephens, Philip

AU - Hunter, Chris

AU - Bignell, Graham

AU - Edkins, Sarah

AU - Davies, Helen

AU - Teague, Jon

AU - Stevens, Claire

AU - O'meara, Sarah

AU - Smith, Raffaella

AU - Parker, Adrian

AU - Barthorpe, Andy

AU - Blow, Matthew

AU - Brackenbury, Lisa

AU - Butler, Adam

AU - Clarke, Oliver

AU - Cole, Jennifer

AU - Dicks, Ed

AU - Dike, Angus

AU - Drozd, Anja

AU - Edwards, Ken

AU - Forbes, Simon

AU - Foster, Rebecca

AU - Gray, Kristian

AU - Greenman, Christopher

AU - Halliday, Kelly

AU - Hills, Katy

AU - Kosmidou, Vivienne

AU - Lugg, Richard

AU - Menzies, Andy

AU - Perry, Janet

AU - Petty, Robert

AU - Raine, Keiran

AU - Ratford, Lewis

AU - Shepherd, Rebecca

AU - Small, Alexandra

AU - Stephens, Yvonne

AU - Tofts, Calli

AU - Varian, Jennifer

AU - West, Sofie

AU - Widaa, Sara

AU - Yates, Andrew

AU - Brasseur, Francis

AU - Cooper, Colin S.

AU - Flanagan, Adrienne M.

AU - Knowles, Margaret

AU - Leung, Suet Y.

AU - Louis, David N.

AU - Looijenga, Leendert H. J.

AU - Malkowicz, Bruce

AU - Pierotti, Marco A.

AU - Teh, Bin

AU - Chenevix-trench, Georgia

AU - Weber, Barbara L.

AU - Yuen, Siu T.

AU - Harris, Grace

AU - Goldstraw, Peter

AU - Nicholson, Andrew G.

AU - Futreal, P. Andrew

AU - Wooster, Richard

AU - Stratton, Michael R.

PY - 2004/9/30

Y1 - 2004/9/30

N2 - The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

AB - The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

KW - Carcinoma, Non-Small-Cell Lung

KW - DNA Mutational Analysis

KW - Enzyme Activation

KW - Humans

KW - Lung Neoplasms

KW - Models, Molecular

KW - Mutation

KW - Neoplasms

KW - Protein Structure, Tertiary

KW - Quinazolines

KW - Receptor, Epidermal Growth Factor

KW - Receptor, erbB-2

U2 - 10.1038/431525b

DO - 10.1038/431525b

M3 - Article

C2 - 15457249

VL - 431

SP - 525

EP - 526

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7008

ER -